Lalwani Nikhil's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Aug 26, 2026
- Accession no.
- 0001822629-26-000014
- Filed
- Aug 26, 2026, 6:15 PM ET
- Trade date
- Aug 25, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $401.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lalwani NikhilCIK 0001822629 | Director, Officer (PRESIDENT & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Common Stock | SSaleDisposed | −5,400 | $74.30F2 | −$401,220 | 344,489 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold in multiple trades at prices ranging from $73.58 to $74.61. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.